Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) saw a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 51,300 shares, a drop of 5.9% from the June 30th total of 54,500 shares. Based on an average daily volume of 8,800 shares, the short-interest ratio is presently 5.8 days. Currently, 1.8% of the company’s shares are sold short.
Eterna Therapeutics Stock Performance
Shares of ERNA opened at $1.81 on Thursday. Eterna Therapeutics has a 1 year low of $0.84 and a 1 year high of $2.91. The company’s 50 day simple moving average is $1.92 and its 200 day simple moving average is $1.93. The company has a market capitalization of $9.79 million, a price-to-earnings ratio of -0.43 and a beta of 4.49. The company has a debt-to-equity ratio of 3.03, a quick ratio of 0.79 and a current ratio of 0.79.
Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.23) earnings per share for the quarter. The business had revenue of $0.05 million during the quarter.
Institutional Trading of Eterna Therapeutics
About Eterna Therapeutics
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Featured Articles
- Five stocks we like better than Eterna Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- Meta Platforms: Rotation or Not, It’s Rally On For This AI Stock
- How to Calculate Inflation Rate
- Humana Slides on Profitability Concerns Despite Q2 Earnings Beat
- Investing In Preferred Stock vs. Common Stock
- Procter & Gamble Stock Drops Despite Earnings Beat – What to Know
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.